November 22, 2016 - By Darrin Black · 0 Comments
Aldeyra Therapeutics (NASDAQ:ALDX) institutional sentiment decreased to 1.14 in 2016 Q2. Its down -0.74, from 1.88 in 2016Q1. The ratio dived, as 15 investment managers started new or increased stock positions, while 8 cut down and sold equity positions in Aldeyra Therapeutics. The investment managers in our partner’s database reported: 6.07 million shares, up from 4.31 million shares in 2016Q1. Also, the number of investment managers holding Aldeyra Therapeutics in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 4 Increased: 13 New Position: 2.
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The company has a market cap of $81.05 million. The Company’s principal activities include raising capital and research and development activities. It currently has negative earnings. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
About 34,283 shares traded hands or 0.87% up from the average. Aldeyra Therapeutics Inc (NASDAQ:ALDX) has risen 8.62% since April 20, 2016 and is uptrending. It has outperformed by 4.06% the S&P500.
According to Zacks Investment Research, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.”
Awm Investment Company Inc. holds 1.12% of its portfolio in Aldeyra Therapeutics Inc for 917,810 shares. Perceptive Advisors Llc owns 1.94 million shares or 0.77% of their US portfolio. Moreover, Sphera Funds Management Ltd. has 0.54% invested in the company for 368,500 shares. The New York-based Knoll Capital Management Lp has invested 0.25% in the stock. Pura Vida Investments Llc, a New York-based fund reported 77,500 shares.#img1#
Ratings analysis reveals 100% of Aldeyra Therapeutics Inc’s analysts are positive. Out of 3 Wall Street analysts rating Aldeyra Therapeutics Inc, 3 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $13 while the high is $18. The stock’s average target of $16.50 is 171.83% above today’s ($6.07) share price. ALDX was included in 4 notes of analysts from August 13, 2015. The firm has “Buy” rating by Stifel Nicolaus given on Friday, July 1. The company was initiated on Tuesday, September 8 by Cowen & Co. The firm earned “Buy” rating on Monday, September 26 by H.C. Wainwright.
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., incorporated on August 13, 2004, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Firm is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Firm has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes.
More news for Aldeyra Therapeutics Inc (NASDAQ:ALDX) were recently published by: Marketwatch.com, which released: “Aldeyra Therapeutics started at buy with $16 stock price target at Stifel Nicolaus” on May 09, 2014. 247Wallst.com‘s article titled: “Why Aldeyra Therapeutics Could Have Exponential Upside” and published on April 04, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black